- Home
- EQX vs JAZZ Comparison
EQX vs JAZZ Comparison
Compare EQX & JAZZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EQX
- JAZZ
- Stock Information
- Founded
- EQX 2007
- JAZZ 2003
- Country
- EQX Canada
- JAZZ Ireland
- Employees
- EQX N/A
- JAZZ N/A
- Industry
- EQX Precious Metals
- JAZZ Biotechnology: Pharmaceutical Preparations
- Sector
- EQX Basic Materials
- JAZZ Health Care
- Exchange
- EQX Nasdaq
- JAZZ Nasdaq
- Market Cap
- EQX 8.4B
- JAZZ 7.9B
- IPO Year
- EQX N/A
- JAZZ 2007
- Fundamental
- Price
- EQX $11.53
- JAZZ $136.58
- Analyst Decision
- EQX Buy
- JAZZ Strong Buy
- Analyst Count
- EQX 1
- JAZZ 14
- Target Price
- EQX $17.00
- JAZZ $179.21
- AVG Volume (30 Days)
- EQX 19.5M
- JAZZ 758.5K
- Earning Date
- EQX 11-05-2025
- JAZZ 11-05-2025
- Dividend Yield
- EQX N/A
- JAZZ N/A
- EPS Growth
- EQX N/A
- JAZZ N/A
- EPS
- EQX N/A
- JAZZ N/A
- Revenue
- EQX $1,905,732,000.00
- JAZZ $4,086,695,000.00
- Revenue This Year
- EQX $65.90
- JAZZ $5.70
- Revenue Next Year
- EQX $49.28
- JAZZ $6.16
- P/E Ratio
- EQX N/A
- JAZZ N/A
- Revenue Growth
- EQX 74.31
- JAZZ 4.52
- 52 Week Low
- EQX $4.95
- JAZZ $95.49
- 52 Week High
- EQX $11.81
- JAZZ $148.06
- Technical
- Relative Strength Index (RSI)
- EQX 73.79
- JAZZ 63.56
- Support Level
- EQX $10.60
- JAZZ $125.79
- Resistance Level
- EQX $11.52
- JAZZ $140.39
- Average True Range (ATR)
- EQX 0.38
- JAZZ 3.18
- MACD
- EQX -0.06
- JAZZ 0.46
- Stochastic Oscillator
- EQX 82.48
- JAZZ 71.59
About EQX Equinox Gold Corp.
Equinox Gold Corp is a mining company engaged in the operation, acquisition, exploration, and development of mineral properties, with a focus on gold. Equinox Gold has around seven operating gold mines and a clear plan to increase production by advancing the pipeline of growth projects. Geographically, the company operates in the United States, Mexico, and Brazil. The majority of its revenue is generated from Canada.
About JAZZ Jazz Pharmaceuticals plc (Ireland)
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.